Fact CheckerSign in

NCT07356284RecruitingPhase 3

Emergent Large Vessel Occlusion Endovascular Rescue Therapy With Underlying Intracranial Stenosis

Source: ClinicalTrials.gov · Last updated 22 May 2026

Brief summary (registry, in English)

The study objective is to establish the safety and efficacy of endovascular adjunct stenting for patients undergoing mechanical thrombectomy (MT) that are found to have residual stenosis (70-99%) following attempted clot retrieval with either aspiration catheters or stent retrievers, per device instructions for use and device labeling.

Status (registry)
Recruiting
Phase (registry)
Phase 3
Study type
Interventional
Enrollment
342 (estimated)
First submitted
20 Jan 2026
Start date
19 May 2026
Primary completion date
1 Jun 2030
Lead sponsor
ProMedica Health System
Diseases
Stroke
NCT number
NCT07356284

What you commit to

  • Study type: Interventional · Phase 3
  • Planned participants: 342
  • From 19 May 2026 to the primary completion date, 1 Jun 2030
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Intracranial tumors other than small meningioma, that do not require surgery for at least one year post randomization. Small meningioma is defined as a lesion measuring ≤20mm in maximum diameter or ≤4cm3 in volume, with no associated mass effect, peritumoral edema, or progressive neurological symptoms
  • Life expectancy less than one year prior to stroke onset

Other illness

  • Known severe allergy (more than a rash) to contrast media uncontrolled by medications.
  • CT evidence of the following conditions:
    • Midline shift or herniation
    • Evidence of intracranial hemorrhage
    • Mass effect with effacement of the ventricles
  • Any other condition (in the opinion of the site investigator) that precludes an endovascular procedure or poses a significant hazard to the patient if an endovascular procedure was performed
  • New diagnosis of atrial fibrillation or a history of atrial fibrillation

Lab values

  • Females who are pregnant, or those of child-bearing potential with positive urine or serum beta Human Chorionic Gonadotropin (HCG) test
  • Known hemorrhagic diathesis, coagulation factor deficiency, or on anticoagulant therapy with an International Normalized Ratio (INR) of \>3.0 or Partial Thromboplastin Time (PTT) \>3 times of normal
  • Baseline platelet count \<80,000 per microliter (µl)

Other

  • Acute bilateral strokes
  • Contraindication to antiplatelet (aspirin, clopidogrel, ticagrelor, cangrelor) or contrast agents
  • Participation in another randomized clinical trial that could confound the evaluation of the study outcomes.
  • Suspected device-induced vasospasm defined as smooth transient narrowing of the target vessel
  • Vessel dissection including any of the following: presence of dissection flap, false lumen, contrast stagnation in the vessel wall, and/or improving stenosis
    • \-

Who the study is looking for

  • 18 to 80 years of age
  • Presenting with symptoms consistent with AIS
  • Imaging evidence of an anterior occlusion of the Internal Carotid Artery (ICA) or Middle Cerebral Artery Main Stem (MCA M1), or proximal M2 segment AND residual 70-99% stenosis of the index artery following attempted clot retrieval with either aspiration catheters or stent retrievers, per device instructions for use and device labeling
  • NIHSS ≥ 6
  • Ability to randomize within 24 hours of stroke onset.
  • Pre-stroke mRS score 0-2
  • Ability to obtain signed informed consent.
  • ASPECTS Score ≥ 6 by non-contrast CT scan
  • Score-ICAD score of ≥11 points at screening and/or persistent stenotic occlusion of ≥70% after MT
  • If indicated, thrombolytic therapy shall be initiated per the institution's usual care and the most recent version of the AHA/ASA Guidelines. Subjects eligible for IV thrombolysis should receive it without delay.
  • For subjects presenting \>6 hours from stroke onset, infarct core volume \<50 cc quantified by CTP

Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
ProMedica Toledo Hospital
Coordinator of this site? Confirm its status
ToledoUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.